As S100A9 was previously linked with venetoclax resistance in AML patients, we examined the effect of S100A9-targeting as potential sensitizer to venetoclax therapy in AML cell lines and primary patient samples. This evidence concerns the gene S100A9 and acute myeloid leukemia.